Assessment of Patient’s Response about Adverse Drug Reactions Receiving AC (Adriamycin, Cyclophosphamide) Therapy: A Survey Research
Jameela Jamali, Abdullah Dayo, Naheed Memon, Ubed-ur-Rehman Mughal, Muhammad Akram Khatri, Shaib Muhammad, Yasmeen Qureshi & Tooba Khan · Journal of Pharmaceutical Research International · 2021
Background: Adverse drug reactions (ADRs) are most common among cancer patients receiving treatment. AC therapy which is a combination protocol of Adriamycin (doxorubicin) and Cyclophosphamide are the common therapies used for breast cancer treatment due to their effectiveness an...
Open access
Research Article
10.9734/jpri/2021/v33i26A31467